Quick facts about menopausal HRT (Hormone Replacement Therapy) preparations
The three types of estrogens - estradiol, estrone and estriol
Do menopausal symptoms reflect a woman’s health status?
Do menopausal symptoms subside over time?
Can menopausal symptoms be affected by lifestyle habits?
Why do some women suffer more than others from menopausal symptoms?
It is not just about estrogen – DHEA, testosterone and cortisol also impact women’s health
Why is Progesterone added to Estrogen in HRT?
Should testosterone be added to estrogen HRT?
Are there any contraindications for estrogen therapy?
Menopause hormone therapy with only testosterone?
1. Morris, E.P. and N. Burbos, Menopausal symptoms. Clin Evid (Online), 2010. 2010.
2. Palacios, S., et al., Age of menopause and impact of climacteric symptoms by geographical region. Climacteric, 2010. 13(5): p. 419-28.
3. Williams, R.E., et al., Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric, 2008. 11(1): p. 32-43.
4. Jokinen, K., et al., Experience of climacteric symptoms among 42-46 and 52-56-year-old women. Maturitas, 2003. 46(3): p. 199-205.
5. Kopper, N.W., J. Gudeman, and D.J. Thompson, Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Des Devel Ther, 2009. 2: p. 193-202.
6. Canonico, M., et al., Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 2007. 115(7): p. 840-5.
7. Campagnoli, C., et al., Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol, 1993. 7(4): p. 251-8.
8. Somboonporn, W., et al., Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev, 2005(4): p. CD004509.
9. Rohr, U.D., The impact of testosterone imbalance on depression and women's health. Maturitas, 2002. 41 Suppl 1: p. S25-46.
10. Nappi, R.E., et al., Menopause and sexual desire: the role of testosterone. Menopause Int, 2010. 16(4): p. 162-8.
11. Rossouw, J.E., et al., Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol, 2013. 121(1): p. 172-6.
12. Lobo, R.A., Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab, 2013. 98(5): p. 1771-80.
13. Wharton, W., et al., Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Res, 2013. 1514: p. 12-7.
14. McBane, S.E., et al., Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy, 2014. 34(4): p. 410-23.
15. Krolik, M. and H. Milnerowicz, The effect of using estrogens in the light of scientific research. Adv Clin Exp Med, 2012. 21(4): p. 535-43.
16. Taylor, M., Unconventional estrogens: estriol, biest, and triest. Clinical Obstetrics and Gynecology, 2001. 44(4): p. 864-79.
17. Head, K.A., Estriol: safety and efficacy. Alternative Medicine Review, 1998. 3(2): p. 101-13.
18. Esposito, G., Estriol: a weak estrogen or a different hormone? Gynecological Endocrinology, 1991. 5(2): p. 131-53.
19. Heimer, G.M., Estriol in the postmenopause. Acta Obstetricia et Gynecologica Scandinavica. Supplement, 1987. 139: p. 1-23.
20. Rapkin, A.J., Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol, 2007. 196(2): p. 97-106.
21. Pinkerton, J.V. and A.S. Zion, Vasomotor symptoms in menopause: where we've been and where we're going. J Womens Health (Larchmt), 2006. 15(2): p. 135-45.
22. Crandall, C.J., et al., Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause, 2009. 16(2): p. 239-46.
23. Thurston, R.C., et al., Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation, 2008. 118(12): p. 1234-40.
24. Jayalath, R.W., S.H. Mangan, and J. Golledge, Aortic calcification. Eur J Vasc Endovasc Surg, 2005. 30(5): p. 476-88.
25. Pines, A., Vasomotor symptoms and cardiovascular disease risk. Climacteric, 2011. 14(5): p. 535-6.
26. Politi, M.C., M.D. Schleinitz, and N.F. Col, Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med, 2008. 23(9): p. 1507-13.
27. Hemminki, E., et al., Variability of bothersome menopausal symptoms over time--a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). BMC Womens Health, 2012. 12: p. 44.
28. Gold, E.B., et al., Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol, 2000. 152(5): p. 463-73.
29. Kroenke, C.H., et al., Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause, 2012. 19(9): p. 980-8.
30. Col, N.F., et al., Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause, 2009. 16(3): p. 453-7.
31. Utian, W.H., Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes, 2005. 3: p. 47.
32. Labrie, F., Impact of circulating dehydroepiandrosterone on androgen formation in women. Menopause, 2011. 18(5): p. 471-3.
33. Labrie, F., C. Martel, and J. Balser, Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause, 2011. 18(1): p. 30-43.
34. Labrie, F., DHEA, important source of sex steroids in men and even more in women. Prog Brain Res, 2010. 182: p. 97-148.
35. Gupta, B., et al., A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause. J Obstet Gynaecol India, 2013. 63(3): p. 194-8.
36. Orentreich, N., et al., Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab, 1984. 59(3): p. 551-5.
37. Labrie, F., et al., Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab, 1997. 82(8): p. 2396-402.
38. Migeon, C.J., et al., Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab, 1957. 17(9): p. 1051-62.
39. Davison, S.L., et al., Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab, 2005. 90(7): p. 3847-53.
40. Woods, N.F., et al., Increased urinary cortisol levels during the menopausal transition. Menopause, 2006. 13(2): p. 212-21.
41. Woods, N.F., E.S. Mitchell, and K. Smith-Dijulio, Cortisol levels during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause, 2009. 16(4): p. 708-18.
42. Meldrum, D.R., et al., Pituitary hormones during the menopausal hot flash. Obstet Gynecol, 1984. 64(6): p. 752-6.
43. Cagnacci, A., et al., Increased cortisol level: a possible link between climacteric symptoms and cardiovascular risk factors. Menopause, 2011. 18(3): p. 273-8.
44. Hadoke, P.W., J. Iqbal, and B.R. Walker, Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol, 2009. 156(5): p. 689-712.
45. Whitworth, J.A., et al., Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag, 2005. 1(4): p. 291-9.
46. Duclos, M., et al., Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res, 2005. 13(7): p. 1157-66.
47. Wallerius, S., et al., Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest, 2003. 26(7): p. 616-9.
48. Poehlman, E.T., Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand, 2002. 81(7): p. 603-11.
49. Toth, M.J., et al., Menopause-related changes in body fat distribution. Ann N Y Acad Sci, 2000. 904: p. 502-6.
50. Shi, H. and D.J. Clegg, Sex differences in the regulation of body weight. Physiol Behav, 2009. 97(2): p. 199-204.
51. Archer, D.F., The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause, 2001. 8(4): p. 245-51.
52. Lacey, J.V., Jr., et al., Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention, 2005. 14(7): p. 1724-31.
53. Ross, R.K., et al., Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute, 2000. 92(4): p. 328-32.
54. Anderson, G.L., et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA, 2004. 291(14): p. 1701-12.
55. Rossouw, J.E., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002. 288(3): p. 321-33.
56. Formby, B. and T.S. Wiley, Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Annals of Clinical Laboratory Science, 1998. 28(6): p. 360-9.
57. Stein, D.G., The case for progesterone. Annals of the New York Academy of Sciences, 2005. 1052: p. 152-69.
58. Silberstein, S.D. and G.R. Merriam, Sex hormones and headache. Journal of Pain and Symptom Management, 1993. 8(2): p. 98-114.
59. Silberstein, S.D., The role of sex hormones in headache. Neurology, 1992. 42(3 Suppl 2): p. 37-42.
60. Silberstein, S.D., Sex hormones and headache. Revue Neurologique, 2000. 156 Suppl 4: p. 4S30-41.
61. Beckham, J.C., et al., The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache, 1992. 32(6): p. 292-7.
62. Colson, N.J., et al., Investigation of hormone receptor genes in migraine. Neurogenetics, 2005. 6(1): p. 17-23.
63. Somerville, B.W., The role of progesterone in menstrual migraine. Neurology, 1971. 21(8): p. 853-9.
64. Nappi, R.E., et al., Hormonal management of migraine at menopause. Menopause Int, 2009. 15(2): p. 82-6.
65. Ambler, D.R., E.J. Bieber, and M.P. Diamond, Sexual function in elderly women: a review of current literature. Rev Obstet Gynecol, 2012. 5(1): p. 16-27.
66. Sarrel, P.M., Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med, 2000. 9 Suppl 1: p. S25-32.
67. Sarrel, P.M., Androgen deficiency: menopause and estrogen-related factors. Fertil Steril, 2002. 77 Suppl 4: p. S63-7.
68. DeCherney, A.H., Hormone receptors and sexuality in the human female. J Womens Health Gend Based Med, 2000. 9 Suppl 1: p. S9-13.
69. Maia, H., Jr., J. Casoy, and J. Valente, Testosterone replacement therapy in the climacteric: benefits beyond sexuality. Gynecol Endocrinol, 2009. 25(1): p. 12-20.
70. Thorneycroft, I.H., et al., Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception, 1999. 60(5): p. 255-62.
71. Strufaldi, R., et al., Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception, 2010. 82(2): p. 147-54.
72. Casson, P.R., et al., Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol, 1997. 90(6): p. 995-8.
73. Turna, B., et al., Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res, 2005. 17(2): p. 148-53.
74. Graham, C.A., et al., Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? Psychoneuroendocrinology, 2007. 32(3): p. 246-55.
75. Floter, A., et al., Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric, 2002. 5(4): p. 357-65.
76. Simon, J., et al., Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab, 2005. 90(9): p. 5226-33.
77. Kingsberg, S.A., J.A. Simon, and I. Goldstein, The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med, 2008. 5 Suppl 4: p. 182-93; quiz 193.
78. Dimitrakakis, C. and C. Bondy, Androgens and the breast. Breast Cancer Res, 2009. 11(5): p. 212.
79. Dimitrakakis, C., et al., A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 2003. 10(4): p. 292-8.
80. Hofling, M., et al., Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause, 2007. 14(2): p. 183-90.
81. Zhou, J., et al., Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J, 2000. 14(12): p. 1725-30.
82. Glaser, R.L. and C. Dimitrakakis, Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas, 2013. 76(4): p. 342-9.
83. Davis, S.R., et al., The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab, 2009. 94(12): p. 4907-13.
84. Davis, S.R., et al., The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med, 2009. 6(7): p. 1850-6.
85. Schwartz, A.G., Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res, 1979. 39(3): p. 1129-32.
86. Labrie, F., et al., Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev, 2003. 24(2): p. 152-82.
87. Glaser, R.L. and C. Dimitrakakis, Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer. Menopause, 2014. 21(6): p. 673-8.
88. de Villiers, T.J., et al., Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2013. 16(3): p. 316-37.
89. Santen, R.J., et al., Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab, 2010. 95(7 Suppl 1): p. s1-s66.